Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer

被引：6

作者：

Morganti, Stefania ^{[1
,2
,3
,4
,5
]}

Tolaney, Sara M. ^{[1
,2
,6
]}

机构：

[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[2] Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA USA

[3] Harvard Med Sch, Boston, MA USA

[4] Broad Inst & Harvard, Boston, MA USA

[5] Univ Milan, Ist Europeo Oncol, Dept Oncol & Hemato Oncol, Milan, Italy

[6] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2023年 / 37卷 / 01期

关键词：

TNBC; Breast cancer; Immunotherapy; Biomarkers; PDL1; Immune checkpoint inhibitors; PEMBROLIZUMAB PLUS CHEMOTHERAPY; PHASE-III TRIAL; NEOADJUVANT CHEMOTHERAPY; DOUBLE-BLIND; PLACEBO; ATEZOLIZUMAB; PACLITAXEL; MELANOMA; TNBC;

D O I：

10.1016/j.hoc.2022.08.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：133 / 150

页数：18

共 58 条

[1] Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]
[2] Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Alva, Ajjai S.
Mangat, Pam K.
Garrett-Mayer, Elizabeth
Halabi, Susan
Hansra, Damien
Calfa, Carmen J.
Khalil, Maged F.
Ahn, Eugene R.
Cannon, Timothy L.
Crilley, Pamela
Fisher, Julie G.
Haslem, Derrick S.
Shrestha, Sagun
Antonelli, Kaitlyn R.
Butler, Nicole L.
Warren, Sasha L.
Rygiel, Andrew L.
Ranasinghe, Shamika
Bruinooge, Suanna S.
Schilsky, Richard L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) : 2443 - +
[3] Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Bachelot, Thomas
Filleron, Thomas
Bieche, Ivan
Arnedos, Monica
Campone, Mario
Dalenc, Florence
Coussy, Florence
Sablin, Marie-Paule
Debled, Marc
Lefeuvre-Plesse, Claudia
Goncalves, Anthony
Reynier, Marie-Ange Mouret
Jacot, William
You, Benoit
Barthelemy, Philippe
Verret, Benjamin
Isambert, Nicolas
Tchiknavorian, Xavier
Levy, Christelle
Thery, Jean-Christophe
L'Haridon, Tifenn
Ferrero, Jean-Marc
Mege, Alice
Del Piano, Francesco
Rouleau, Etienne
Tran-Dien, Alicia
Adam, Julien
Lusque, Amelie
Jimenez, Marta
Jacquet, Alexandra
Garberis, Ingrid
Andre, Fabrice
[J]. NATURE MEDICINE, 2021, 27 (02) : 250 - +
[4] Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)
Barroso-Sousa, Romualdo
Li, Tianyu
Reddy, Sangeetha
Emens, Leisha A.
Overmoyer, Beth
Lange, Paulina
Dilullo, Molly K.
Attaya, Victoria
Kimmel, Jeffrey
Winer, Eric P.
Mittendorf, Elizabeth A.
Tayob, Nabihah
Tolaney, Sara M.
[J]. CANCER RESEARCH, 2022, 82 (04)
[5] Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Barroso-Sousa, Romualdo
Keenan, Tanya E.
Pernas, Sonia
Exman, Pedro
Jain, Esha
Garrido-Castro, Ana C.
Hughes, Melissa
Bychkovsky, Brittany
Umeton, Renato
Files, Janet L.
Lindeman, Neal I.
MacConaill, Laura E.
Hodi, F. Stephen
Krop, Ian E.
Dillon, Deborah
Winer, Eric P.
Wagle, Nikhil
Lin, Nancy U.
Mittendorf, Elizabeth A.
Van Allen, Eliezer M.
Tolaney, Sara M.
[J]. CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2565 - 2572
[6] Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
Bianchini, G.
Huang, C-S.
Egle, D.
Bermejo, B.
Zamagni, C.
Thill, M.
Anton, A.
Zambelli, S.
Russo, S.
Ciruelos, E. M.
Greil, R.
Semiglazov, V.
Colleoni, M. A.
Kelly, C. M.
Mariani, G.
Del Mastro, L.
Smart, C.
Valagussa, P.
Viale, G.
Gianni, L.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1145 - S1146
[7] Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
Bianchini, Giampaolo
De Angelis, Carmine
Licata, Luca
Gianni, Luca
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (02) : 91 - 113
[8] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Burstein, H. J.
Curigliano, G.
Thurlimann, B.
Weber, W. P.
Poortmans, P.
Regan, M. M.
Senn, H. J.
Winer, E. P.
Gnant, M.
[J]. ANNALS OF ONCOLOGY, 2021, 32 (10) : 1216 - 1235
[9] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Cortazar, Patricia
Zhang, Lijun
Untch, Michael
Mehta, Keyur
Costantino, Joseph P.
Wolmark, Norman
Bonnefoi, Herve
Cameron, David
Gianni, Luca
Valagussa, Pinuccia
Swain, Sandra M.
Prowell, Tatiana
Loibl, Sibylle
Wickerham, D. Lawrence
Bogaerts, Jan
Baselga, Jose
Perou, Charles
Blumenthal, Gideon
Blohmer, Jens
Mamounas, Eleftherios P.
Bergh, Jonas
Semiglazov, Vladimir
Justice, Robert
Eidtmann, Holger
Paik, Soonmyung
Piccart, Martine
Sridhara, Rajeshwari
Fasching, Peter A.
Slaets, Leen
Tang, Shenghui
Gerber, Bernd
Geyer, Charles E., Jr.
Pazdur, Richard
Ditsch, Nina
Rastogi, Priya
Eiermann, Wolfgang
von Minckwitz, Gunter
[J]. LANCET, 2014, 384 (9938) : 164 - 172
[10] Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9

← 1 2 3 4 5 6 →